A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes. Reumatismo [Internet]. 2025 May 8 [cited 2026 Apr. 28];77(3). Available from: https://www.reumatismo.org/reuma/article/view/1748